Drug delivery nanosystems in glioblastoma multiforme treatment: Current state of the art

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.creatorDi Filippo, Leonardo Delello [UNESP]-
Autor(es): dc.creatorDuarte, Jonatas Lobato [UNESP]-
Autor(es): dc.creatorLuiz, Marcela Tavares-
Autor(es): dc.creatorde Araújo, Jennifer Thayanne Cavalcante [UNESP]-
Autor(es): dc.creatorChorilli, Marlus [UNESP]-
Data de aceite: dc.date.accessioned2022-02-22T00:54:16Z-
Data de disponibilização: dc.date.available2022-02-22T00:54:16Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2020-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.2174/1570159X18666200831160627-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/208730-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/208730-
Descrição: dc.descriptionGlioblastoma multiforme (GBM) is the most common primary malignant Central Nervous System cancer, responsible for about 4% of all deaths associated with neoplasia, characterized as one of the fatal human cancers. Tumor resection does not possess curative character, thereby radio and/or chemotherapy are often necessary for the treatment of GBM. However, drugs used in GBM chemotherapy present some limitations, such as side effects associated with non-specific drug biodistribution as well as limited bioavailability, which limits their clinical use. To attenuate the systemic toxicity and overcome the poor bioavailability, a very attractive approach is drug encapsulation in drug delivery nanosystems. The main focus of this review is to explore the actual cancer global problem, enunciate barriers to overcome in the pharmacological treatment of GBM, as well as the most updated drug delivery nanosystems for GBM treatment and how they influence biopharmaceutical properties of anti-GBM drugs. The discussion will approach lipid-based and polymeric nanosystems, as well as inorganic nanoparticles, regarding their technical aspects as well as biological effects in GBM treatment. Furthermore, the current state of the art, challenges to overcome and future perspectives in GBM treatment will be discussed.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP)-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo (USP)-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP)-
Descrição: dc.descriptionFAPESP: 2018/ 18488-3-
Formato: dc.format787-812-
Idioma: dc.languageen-
Relação: dc.relationCurrent Neuropharmacology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectBrain cancer-
Palavras-chave: dc.subjectCancer therapy-
Palavras-chave: dc.subjectInorganic nanoparticles-
Palavras-chave: dc.subjectLipid-based systems-
Palavras-chave: dc.subjectPharmaceutical nanotechnology-
Palavras-chave: dc.subjectPolymeric systems-
Título: dc.titleDrug delivery nanosystems in glioblastoma multiforme treatment: Current state of the art-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.